Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
acceptability ‐ drop‐outs due to adverse events: post‐intervention · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Acceptability · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to any cause: post‐intervention compared with placebo (very low certainty).
2 findings from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Acceptability · adults with long‐term physical conditions (18 years or older)
Psychological interventions may leads to higher acceptability ‐ drop‐outs due to any cause: post‐intervention compared with treatment (low certainty).
2 findings from 1 review
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
Atypical showed no clear difference in diabetes (ADA criteria) (6 weeks) compared with typical antipsychotic medications (low certainty).
1 finding from 1 review
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Melatonin showed no clear difference in drop‐outs (8 weeks) compared with placebo (low certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Fasting blood glucose (8 to 12 weeks) (change from baseline data) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Atypical showed no clear difference in drop‐outs (6 to 54 weeks) compared with typical antipsychotic medications (low certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Metformin showed no clear difference in drop‐outs (12 to 14 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
2 findings from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review